However, CCA is extremely toxic, and the industry has since outlawed the use of it in projects for residential use.Įxisting decks and other projects constructed with CCA-treated wood pose no immediate danger. Until 2003, the most commonly used chemical to treat lumber was chromated copper arsenate, or CCA. Also remember that pressure-treated wood is for outdoor use only. Take the appropriate safety measures when handling pressure-treated wood, including wearing safety goggles, gloves, and a mask. Warning: Pressure-treated wood can be toxic to humans and pets. However, this process has both pros and cons, as some chemicals used can be toxic. This makes the wood less likely to rot as well as unappealing to insects and vermin, which is ideal for outside wood projects.
The Cmax/ki ratio was 0.007, well below the threshold for clinical DDI evaluation as recommended in regulatory guidances, thereby suggesting efinaconazole 10% solution has remote potential for drug-drug interactions.When wood is pressure-treated, a chemical preservative is forced into it. Efinaconazole is a CYP inhibitor like other azole antifungals, and its lowest ki is 91 ng/mL for CYP2C9, a >130-fold higher concentration than the mean steady state Cmax observed in patients. Efinaconazole was well tolerated in both studies no drug-related adverse events were reported.Įfinaconazole 10% solution resulted in very low systemic exposures to efinaconazole and H3 when applied topically at maximum use conditions to healthy volunteer and onychomycosis patients' toenails. Both parent drug and metabolite accumulated following repeat dosing, and reached steady state in plasma by 14 days. The mean peak plasma concentrations (Cmax) of efinaconazole and H3 were 0.54 and 1.63 ng/mL, respectively, in healthy volunteers and 0.67 and 2.36 ng/mL, respectively, in patients. Safety evaluations were carried out throughout both studies. Plasma concentrations of efinaconazole and its major metabolite H3 were determined by LC-MS-MS at multiple timepoints. Efinaconazole 10% solution was applied topically to all 10 toenails (0.42 mL total daily dose volume) administered as single and then 7 daily doses to 10 healthy volunteers, and once daily for 28 days to 19 severe onychomycosis patients. Two single-center, open-label studies in healthy volunteers and severe onychomycosis patients. To characterize the systemic exposure and pharmacokinetics of efinaconazole 10% solution and assess the potential for drug-drug interaction (DDI) in human volunteers and onychomycosis patients following topical administration.
0 kommentar(er)
